The latest price target for Axsome Therapeutics (NASDAQ:AXSM) was reported by UBS on April 10, 2026. The analyst firm set a price target for $259.00 expecting AXSM to rise to within 12 months (a possible 37.02% upside). 42 analyst firms have reported ratings in the last year.

The latest analyst rating for Axsome Therapeutics (NASDAQ:AXSM) was provided by UBS, and Axsome Therapeutics maintained their buy rating.

The last upgrade for Axsome Therapeutics Inc happened on August 6, 2024 when B of A Securities raised their price target to $106. B of A Securities previously had a neutral for Axsome Therapeutics Inc.

The last downgrade for Axsome Therapeutics Inc happened on January 8, 2026 when Morgan Stanley changed their price target from $196 to $204 for Axsome Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axsome Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axsome Therapeutics was filed on April 10, 2026 so you should expect the next rating to be made available sometime around April 10, 2027.

While ratings are subjective and will change, the latest Axsome Therapeutics (AXSM) rating was a maintained with a price target of $251.00 to $259.00. The current price Axsome Therapeutics (AXSM) is trading at is $189.02, which is out of the analyst’s predicted range.